Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-07EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
EMA authorised Scemblix (asciminib hydrochloride) for chronic myeloid leukemia with BCR-ABL positive status.
-
EMA approval · 2026-07-20EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
Scemblix (asciminib hydrochloride) has been authorised in the EU for chronic myeloid leukemia positive for BCR-ABL, with orphan designation.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System [Phase 3]
Phase 3 trial update on discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia and its impact on the immune system.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System [Phase 3]
Phase 3 trial update regarding discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia and its effects on the immune syste…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Natural Killer Cells and Bortezomib to Treat Cancer [Phase 1]
This Phase 1 clinical trial update reports on the combination of natural killer cells and bortezomib for several cancers, and the study has …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP [Phase 2]
A Phase 2 clinical trial update for asciminib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chroni…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
A clinical trial update on Asciminib for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Germany, focusing on …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia [Phase 1]
Phase I clinical trial update for decitabine, lisaftoclax, and olverembatinib in advanced chronic myeloid leukemia and Philadelphia chromoso…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator [Phase 4]
Phase 4 trial extension allowing access to imatinib for patients currently on imatinib in a Novartis-sponsored study who are judged by inves…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. [Phase 2]
Open-label phase 2 trial of asciminib for chronic myeloid leukemia in chronic or accelerated phase with the T315I mutation who are resistant…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Asciminib RMP Study
Update on Asciminib's risk management plan study for chronic myeloid leukemia; the trial is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) [Phase 2]
A Phase 2 clinical trial evaluating asciminib, alone or in combination with dasatinib, as second-line therapy for chronic myeloid leukemia i…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT [Phase 1]
Stanford is conducting a Phase 1 study evaluating cessation of tacrolimus immunosuppression after allogeneic hematopoietic cell transplantat…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase [Phase 2]
A Phase II clinical trial evaluating olverembatinib as monotherapy for newly diagnosed chronic phase chronic myeloid leukemia; the study is …
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
A chart-review study by MD Anderson Cancer Center investigates outcomes of Chronic Myeloid Leukemia patients who were treated with imatinib …
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors [Phase 1, Phase 2]
The document reports ongoing Phase 1/2 clinical trials evaluating ponatinib in pediatric patients with recurrent or refractory leukemias, ly…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments
Expanded access update for vodobatinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia who have not responded to …
-
FDA approval · 2026-04-14FDA Approved: DANZITEN — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Danziten (nilotinib) submitted by Azurity Pharmaceuticals, Inc. The supplement adds to the e…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial update. It evaluates a conditioning strategy using chemotherapy, total body irradiation, and post-transpl…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Pfizer is recruiting adults with chronic myeloid leukemia for a clinical trial of Bosulif (bosutinib) to study its safety and potential effi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy [Phase 1]
Phase 1 clinical trial sponsored by the University of Alabama at Birmingham evaluating UAB 2419-CD34 selection using the CliniMACS Prodigy s…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia [Phase 2]
Phase 2 clinical trial update evaluating whether stopping tyrosine kinase inhibitors can influence treatment-free remission in patients with…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Prospective collection, storage, and reporting of data on patients undergoing hematopoietic stem cell transplantation using a standard prepa…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A multicenter protocol to improve access and distribution of unlicensed cryopreserved cord blood units, with the study currently recruiting.…
-
EMA approval · 2026-04-09EMA Authorised: Iclusig (ponatinib) — Incyte Biosciences Distribution B.V.
The European Medicines Agency authorised Iclusig (ponatinib) from Incyte Biosciences Distribution B.V. for certain leukemias, including chro…